Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
2020-04-10 |
| gptkbp:approvedBy |
gptkb:neurofibromatosis_type_1
|
| gptkbp:ATCCode |
gptkb:L01EE04
|
| gptkbp:brand |
gptkb:Koselugo
|
| gptkbp:CASNumber |
606143-52-6
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
5-8 hours
|
| gptkbp:hasMolecularFormula |
C17H11BrClFN4O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
selumetinib
|
| gptkbp:indication |
pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
98%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201837
10127622 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain fatigue rash |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:UNII |
3W8Q175KF1
|
| gptkbp:bfsParent |
gptkb:MEK1
gptkb:MEK_inhibitors |
| gptkbp:bfsLayer |
6
|